pyrroloquinoline and Osteolysis

pyrroloquinoline has been researched along with Osteolysis* in 1 studies

Other Studies

1 other study(ies) available for pyrroloquinoline and Osteolysis

Article	Year
Pyrroloquinoline quinine inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos in mouse bone marrow cells and inhibits wear particle-induced osteolysis in mice. PloS one, 2013, Volume: 8, Issue:4 The effects of pyrroloquinoline quinine (PQQ) on RANKL-induced osteoclast differentiation and on wear particle-induced osteolysis were examined in this study. PQQ inhibited RANKL-mediated osteoclast differentiation in bone marrow macrophages (BMMs) in a dose-dependent manner without any evidence of cytotoxicity. The mRNA expression of c-Fos, NFATc1, and TRAP in RANKL-treated BMMs was inhibited by PQQ treatment. Moreover, RANKL-induced c-Fos and NFATc1 protein expression was suppressed by PQQ. PQQ additionally inhibited the bone resorptive activity of differentiated osteoclasts. Further a UHMWPE-induced murine calvaria erosion model study was performed to assess the effects of PQQ on wear particle-induced osteolysis in vivo. Mice treated with PQQ demonstrated marked attenuation of bone erosion based on Micro-CT and histologic analysis of calvaria. These results collectively suggested that PQQ demonstrated inhibitory effects on osteoclast differentiation in vitro and may suppress wear particle-induced osteolysis in vivo, indicating that PQQ may therefore serve as a useful drug in the prevention of bone loss. Topics: Acid Phosphatase; Animals; Bone Marrow Cells; Cell Death; Cell Differentiation; Gene Expression Regulation; Isoenzymes; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteolysis; Polyethylenes; Proto-Oncogene Proteins c-fos; Pyrroles; Quinine; Quinolines; RANK Ligand; RNA, Messenger; Skull; Tartrate-Resistant Acid Phosphatase; X-Ray Microtomography	2013

Article

Year

Pyrroloquinoline quinine inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos in mouse bone marrow cells and inhibits wear particle-induced osteolysis in mice.

PloS one, 2013, Volume: 8, Issue:4

The effects of pyrroloquinoline quinine (PQQ) on RANKL-induced osteoclast differentiation and on wear particle-induced osteolysis were examined in this study. PQQ inhibited RANKL-mediated osteoclast differentiation in bone marrow macrophages (BMMs) in a dose-dependent manner without any evidence of cytotoxicity. The mRNA expression of c-Fos, NFATc1, and TRAP in RANKL-treated BMMs was inhibited by PQQ treatment. Moreover, RANKL-induced c-Fos and NFATc1 protein expression was suppressed by PQQ. PQQ additionally inhibited the bone resorptive activity of differentiated osteoclasts. Further a UHMWPE-induced murine calvaria erosion model study was performed to assess the effects of PQQ on wear particle-induced osteolysis in vivo. Mice treated with PQQ demonstrated marked attenuation of bone erosion based on Micro-CT and histologic analysis of calvaria. These results collectively suggested that PQQ demonstrated inhibitory effects on osteoclast differentiation in vitro and may suppress wear particle-induced osteolysis in vivo, indicating that PQQ may therefore serve as a useful drug in the prevention of bone loss.

Topics: Acid Phosphatase; Animals; Bone Marrow Cells; Cell Death; Cell Differentiation; Gene Expression Regulation; Isoenzymes; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteolysis; Polyethylenes; Proto-Oncogene Proteins c-fos; Pyrroles; Quinine; Quinolines; RANK Ligand; RNA, Messenger; Skull; Tartrate-Resistant Acid Phosphatase; X-Ray Microtomography

2013